Are Mega-Mergers Back?
Summary
Hosts Travis Hoy, Lou Whiteman, and Rachel Warren discuss the potential AstraZeneca-Bristol-Myers Squibb merger, highlighting regulatory hurdles and strategic concerns. They analyze rising interest rates, noting that surging bond yields reflect shaken Federal Reserve credibility rather than just economic health. The episode also covers a busy earnings week, focusing on AI valuation tests for Palantir and AMD, consumer spending trends, and SpaceX’s need for a clearer near-term narrative.
Topics discussed
Introduction and AstraZeneca-BMS merger news
Analysis of AstraZeneca and Bristol-Myers Squibb merger rumors
M&A trends, antitrust concerns, and regulatory outlook
Ad: Claude AI for investors
Rising interest rates and Federal Reserve credibility and bond markets
Divergence between stock and bond market signals
Ads: Vanguard Investor Choice and Range Rover
Earnings week preview: AI, consumer spending, and Disney
SpaceX earnings focus: Narrative and long-term vision
Uber growth analysis and show conclusion
Listen ad-free on Castria